CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
急性髓系白血病中 CAR-T 细胞靶点识别的新方法
英文原题：Novel approaches to CAR T cell target identification in acute myeloid leukemia.
查看英文原题
Novel approaches to CAR T cell target identification in acute myeloid leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性髓系白血病（AML）具有复杂性，且与正常造血系统存在重叠，因此寻找安全有效的CAR-T 细胞靶点颇具挑战。本综述重点介绍AML靶点发现的进展和创新方法。结构表面组学可鉴定肿瘤特异性蛋白构象；AI驱动的单细胞RNA测序整合多来源数据，以确定最佳靶点；改良细胞表面捕获技术则无需预先指定抗体即可绘制AML细胞表面蛋白组。这些策略有望提高CAR-T 细胞特异性并减少瘤外效应，为更安全有效的AML治疗及更广泛的癌症治疗提供新途径。
展开英文摘要原文
Identifying safe and effective CAR T cell targets in acute myeloid leukemia (AML) is challenging due to the disease's complexity and overlap with normal hematopoiesis. This review highlights advances in target discovery for AML, emphasizing innovative approaches. Structural surfaceomics identifies tumor-specific protein conformations, while AI-driven single-cell RNA sequencing integrates multi-source data to pinpoint optimal targets.
Refined cell surface capture technology maps the AML surfaceome without relying on predefined antibodies. These strategies enhance CAR T cell specificity and minimize off-tumor effects, offering promising pathways for safer and more effective AML treatments and broader cancer therapies.
论文信息
- 作者
- Hoffmann GV、Gottschlich A、Subklewe M、Kobold S
- 第一作者单位
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.Germany
- 通讯作者单位
- Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Munich, Research Center for Environmental Health (HMGU), Neuherberg, Germany. Electronic address: Sebastian.kobold@med.uni-muenchen.de.Germany
- 文献类型
- 综述
- 期刊
- Current opinion in pharmacology2025 Jun
- 原文标识
- PubMed 40311558 · DOI 10.1016/j.coph.2025.102524